{"title":"重度哮喘慢性呼吸衰竭-生物治疗后的问题解答,1例临床病例","authors":"J. Branco, F. Todo Bom, S. Furtado","doi":"10.32932/rpia.2021.09.066","DOIUrl":null,"url":null,"abstract":"Severe asthma is defined as either refractory to traditional therapies or controlled only with therapies that have intolerable side effects. Biological agents are known to offer treatment alternatives to patients with type 2 inflammation severe asthma. We describe the case of a woman with a long history of type 2 inflammation severe asthma, with uncontrolled symptoms and need of systemic corticosteroid therapy as prevailing features, and with respiratory failure that differentiated her from other patients with severe asthma.","PeriodicalId":21399,"journal":{"name":"Revista Portuguesa de Imunoalergologia","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chronic respiratory failure in severe asthma – Questions answered after biological therapy, a clinical case\",\"authors\":\"J. Branco, F. Todo Bom, S. Furtado\",\"doi\":\"10.32932/rpia.2021.09.066\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Severe asthma is defined as either refractory to traditional therapies or controlled only with therapies that have intolerable side effects. Biological agents are known to offer treatment alternatives to patients with type 2 inflammation severe asthma. We describe the case of a woman with a long history of type 2 inflammation severe asthma, with uncontrolled symptoms and need of systemic corticosteroid therapy as prevailing features, and with respiratory failure that differentiated her from other patients with severe asthma.\",\"PeriodicalId\":21399,\"journal\":{\"name\":\"Revista Portuguesa de Imunoalergologia\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Portuguesa de Imunoalergologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32932/rpia.2021.09.066\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Portuguesa de Imunoalergologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32932/rpia.2021.09.066","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Chronic respiratory failure in severe asthma – Questions answered after biological therapy, a clinical case
Severe asthma is defined as either refractory to traditional therapies or controlled only with therapies that have intolerable side effects. Biological agents are known to offer treatment alternatives to patients with type 2 inflammation severe asthma. We describe the case of a woman with a long history of type 2 inflammation severe asthma, with uncontrolled symptoms and need of systemic corticosteroid therapy as prevailing features, and with respiratory failure that differentiated her from other patients with severe asthma.